werewolf therapeutics | Home Page | Werewolf Therapeutics Inc.

Keyword	CPC	PCC	Volume	Score	Length of keyword
werewolf therapeutics	0.39	0.7	6516	86	21
werewolf	0.21	0.7	9814	86	8
therapeutics	1.22	0.8	3357	94	12

Keyword	CPC	PCC	Volume	Score
werewolf therapeutics	1.09	0.2	9886	49
werewolf therapeutics stock forecast	0.66	0.1	7954	31
werewolf therapeutics stock	1.61	0.7	956	98
werewolf therapeutics news	0.38	1	9995	19
werewolf therapeutics il-2	1.05	0.3	5820	52
werewolf therapeutics watertown ma	0.85	1	727	100
werewolf therapeutics ipo	0.48	0.6	6778	63
werewolf therapeutics logo	0.6	0.5	7440	97
werewolf therapeutics ticker	0.6	0.4	1100	41
werewolf therapeutics pipeline	1.55	0.1	7456	85
werewolf therapeutics watertown	1.66	0.1	9994	10
werewolf therapeutics inc. howl	1.09	0.7	2716	33
werewolf therapeutics market cap	1.87	1	4006	24
werewolf therapeutics phone number	0.16	0.9	8104	1
howl werewolf therapeutics	0.51	0.4	2964	16
ellen lubman werewolf therapeutics	0.96	0.9	6547	75

Search Results related to werewolf therapeutics on Search Engine

Home Page | Werewolf Therapeutics Inc.
werewolftx.com

https://werewolftx.com/

WEBMar 7, 2024 · We create systemically delivered targeted therapies that address the limitations of immuno-oncology. Werewolf Therapeutics is a highly innovative company striving to redefine the cancer treatment landscape with potential best-in-class therapies. OUR GOAL IS TO TRANSFORM THE LIVES OF CANCER PATIENTS.

DA: 8 PA: 4 MOZ Rank: 42 Up or Down: Up

Our Approach | Werewolf Therapeutics Inc.
werewolftx.com

https://werewolftx.com/our-pipeline/

WEBWerewolf Therapeutics is advancing a novel class of conditionally activated proinflammatory immune modulators designed to act selectively within the tumor microenvironment and recruit a powerful anti-tumor immune response.

DA: 96 PA: 18 MOZ Rank: 72 Up or Down: Up

Our Team | Werewolf Therapeutics Inc.
werewolftx.com

https://werewolftx.com/our-team/

WEBWerewolf Therapeutics is backed by leading life science investors and led by an experienced team with a proven track record of developing novel medicines for the treatment of cancer.

DA: 55 PA: 28 MOZ Rank: 100 Up or Down: Up

Werewolf Therapeutics, Inc. (HOWL) - Yahoo Finance
yahoo.com

https://finance.yahoo.com/quote/HOWL

WEBWerewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer.

DA: 18 PA: 15 MOZ Rank: 81 Up or Down: Up

Werewolf Therapeutics Presents Preliminary Monotherapy Data …
werewolftx.com

https://investors.werewolftx.com/news-releases/news-release-details/werewolf-therapeutics-presents-preliminary-monotherapy-data

WEBNov 3, 2023 · Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting. November 3, …

DA: 32 PA: 66 MOZ Rank: 94 Up or Down: Up

Our Science | Werewolf Therapeutics Inc.
werewolftx.com

https://werewolftx.com/our-science/

WEBPredator™ Protein Engineering. Our proprietary PREDATOR™ protein engineering technology allows us to achieve immune targeting and conditional activation in a new way, enabling the development of novel therapies designed to:

DA: 63 PA: 82 MOZ Rank: 18 Up or Down: Up

News & Resources | Werewolf Therapeutics, Inc.
werewolftx.com

https://investors.werewolftx.com/news-and-events/press-releases

WEBWerewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook. - Prioritizing development of wholly owned clinical assets, WTX-124 and WTX-330; key updates from both INDUKINE TM programs anticipated in 2024 - - WTX-124: updated interim monotherapy dose-escalation data and initial combination dose escalation data …

DA: 32 PA: 57 MOZ Rank: 46 Up or Down: Up

Investors | Werewolf Therapeutics, Inc.
werewolftx.com

https://investors.werewolftx.com/

WEBNov 29, 2023 · Werewolf Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that …

DA: 68 PA: 2 MOZ Rank: 70 Up or Down: Up

Werewolf Therapeutics Provides Business Update and Highlights …
werewolftx.com

https://investors.werewolftx.com/news-releases/news-release-details/werewolf-therapeutics-provides-business-update-and-highlights

WEBJan 8, 2024 · About Werewolf Therapeutics: Werewolf Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer.

DA: 28 PA: 85 MOZ Rank: 79 Up or Down: Up

Werewolf Therapeutics Presents Preliminary Monotherapy Data …
yahoo.com

https://finance.yahoo.com/news/werewolf-therapeutics-presents-preliminary-monotherapy-110000471.html

WEBWATERTOWN, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development...

DA: 10 PA: 3 MOZ Rank: 51 Up or Down: Up